Salmonella (e.g., Salmonella Typhimurium, Etc.) Patents (Class 424/258.1)
  • Patent number: 10087451
    Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: October 2, 2018
    Assignee: Aviex Technologies LLC
    Inventor: David Gordon Bermudes
  • Patent number: 9750793
    Abstract: A recombineered Salmonella typhi Ty21a, compositions and vaccines comprising such a Ty21a, and a method for recombineering comprising inserting a large antigenic region into a bacterial chromosome for the purpose of making multivalent vaccines to protect against one or more disease agents are described herein.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: September 5, 2017
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Madushini Nirosha Dharmasena, Dennis J. Kopecko
  • Patent number: 9421252
    Abstract: Gram-negative bacterial mutants resistant stress conditions, including CO2, acid pH, and high osmolarity are provided, having reduced TNF-? induction having a msbB mutation, that are rendered stress-resistant by a mutation in the zwf gene. A method for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject attenuated stress-resistant gram-negative bacterial mutants, is also provided, along with Methods for prophylaxis or treatment of a virally induced disease in a subject comprise administering to said subject one or more stress-resistant gram-negative bacterial mutants as vectors for the delivery of one or more therapeutic molecules. The methods provide efficient delivery of therapeutic molecules by stress-resistant gram-negative bacterial mutants engineered to express said therapeutic molecules.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: August 23, 2016
    Assignee: AVIEX TECHNOLOGIES, LLC
    Inventor: David Gordon Bermudes
  • Patent number: 9315817
    Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: April 19, 2016
    Inventor: David Gordon Bermudes
  • Patent number: 9040059
    Abstract: The present invention encompasses recombinant bacteria and immunogenic compositions comprising the bacteria. The immunogenic composition may be used to induce an immune response against C. perfringens.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: May 26, 2015
    Assignee: The Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Bereket Zekarias, Kenneth Roland
  • Patent number: 9011871
    Abstract: The present invention is drawn to multivalent Salmonella enterica serovar conjugate vaccines comprising conjugates of S. Typhimurium, S. Enteritidis, S. Choleraesuis, S. Typhi, S. Paratyphi A and optionally S. Paratyphi B, wherein the conjugates comprise a hapten antigen and a carrier antigen, wherein at least one of the hapten antigens or carrier antigens is characteristic of the Salmonella enterica serovar. The present invention also provides Salmonella enterica serovar reagent strains to produce the multivalent conjugate vaccines and attenuated Salmonella enterica serovars for use as vaccines.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 21, 2015
    Assignee: University of Maryland, Baltimore
    Inventors: Myron M. Levine, James E. Galen, Sharon M. Tennant, Raphael Simon
  • Patent number: 8992943
    Abstract: Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: March 31, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dennis J. Kopecko, De-Qi Xu, John O. Cisar
  • Publication number: 20150086590
    Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.
    Type: Application
    Filed: February 19, 2013
    Publication date: March 26, 2015
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ryuichi Sakamoto, Masashi Sakaguchi
  • Patent number: 8932609
    Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: January 13, 2015
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Publication number: 20140370057
    Abstract: The present invention relates to inducing acid resistance in a bacterium and methods of increasing the acid resistance of an acid sensitive bacterium.
    Type: Application
    Filed: June 17, 2014
    Publication date: December 18, 2014
    Inventors: Roy Curtiss, III, Karen Brenneman, Kenneth Roland
  • Patent number: 8900623
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 2, 2014
    Assignee: Vetech Laboratories Inc.
    Inventor: Eng-Hong Lee
  • Publication number: 20140328876
    Abstract: In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
    Type: Application
    Filed: November 16, 2012
    Publication date: November 6, 2014
    Inventor: Maura Ellen Campbell
  • Patent number: 8871215
    Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: October 28, 2014
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Patent number: 8834891
    Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: September 16, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Jeremy Kroll, Mike Roof
  • Publication number: 20140242117
    Abstract: The present investigation relates to entrapment of carbohydrate antigen such as Vi polysaccharide of Salmonella typhi in poly (DL) lactide (PDLLA) and polylactide-co-glycolide (PLGA) polymer particles. The formulated product not only elicits primary antibody titers from single dose application but also evokes memory antibody titer against the T independent antigen.
    Type: Application
    Filed: May 29, 2012
    Publication date: August 28, 2014
    Applicant: National Institute of Immunology
    Inventors: Anish Chakkumkal, Amulya Kumar Panda
  • Publication number: 20140199345
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 17, 2014
    Inventors: Carla Christina Schrier, Simon Ilg
  • Publication number: 20140193457
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 10, 2014
    Inventors: Carla Christina Schrier, Simon ILG
  • Publication number: 20140186398
    Abstract: The disclosure features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA), as well as the methods of using the vaccine compositions. Further disclosed are the structural features of the prokaryotic mRNA used as the adjuvants.
    Type: Application
    Filed: July 17, 2012
    Publication date: July 3, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Julie Magarian Blander, Leif Erik Sander
  • Publication number: 20140186399
    Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicant: President and Fellows of Harvard College
    Inventor: John J. MEKALANOS
  • Publication number: 20140186401
    Abstract: In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a Salmonella strain comprising a plasmid that expresses an shRNA molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth. In some aspects, the Salmonella strain is an attenuated Salmonella typhimurium strain. In other aspects, the immunosuppressive target is STAT3, IDO1, IDO2, Arginase 1, iNOS, CTLA-4, TGF-?, IL-10, pGE2 or VEGF. In one embodiment, the immunosuppressive target is IDO1 or Arg1 and the shRNA molecule is any one of SEQ ID NO:5-14.
    Type: Application
    Filed: October 28, 2013
    Publication date: July 3, 2014
    Inventors: Don J. Diamond, Edwin Manuel, Fernanda V.V. Castro
  • Patent number: 8753649
    Abstract: Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: June 17, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Che-Hung Robert Lee, Carl E. Frasch
  • Publication number: 20140127263
    Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 8, 2014
    Applicant: OmniGen Research, L.L.C.
    Inventors: Neil E. Forsberg, Steven B. Puntenney
  • Patent number: 8703153
    Abstract: The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: April 22, 2014
    Inventors: Jonathan Lewis Telfer, Mark Richard Redfern, Michael Joseph Lacy
  • Patent number: 8703152
    Abstract: Methods and products are disclosed for treating an inflammatory intestinal disease in a mammalian subject in need thereof, or preventing or reducing a symptom of inflammatory intestinal disease. These method include administering to the subject a therapeutically effective dose of (i) an isolated AvrA protein or polypeptide fragment thereof or (ii) a nucleic acid molecule encoding the isolated AvrA protein or polypeptide fragment. Preferred inflammatory intestinal diseases include Inflammatory Bowel Disease, Celiac Disease, and gastroenteritis.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: April 22, 2014
    Assignee: University of Rochester
    Inventor: Jun Sun
  • Publication number: 20140086989
    Abstract: The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration.
    Type: Application
    Filed: May 15, 2012
    Publication date: March 27, 2014
    Applicant: Matrivax, Inc.
    Inventors: Kevin P. Killeen, Robert T. Cartee
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Patent number: 8658136
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: February 25, 2014
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Patent number: 8647640
    Abstract: The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus Salmonella, Listeria, Pseudomonas, Staphylococcus, and Vibrio. Kits are also encompassed for detection, diagnosis and prevention of microorganism-associated disease.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: February 11, 2014
    Inventor: Richard E. Cowart
  • Patent number: 8647642
    Abstract: Gram-negative bacteria, and compositions containing the bacteria, resistant to one or more stress conditions, including, but not limited to, CO2, acid pH, and high osmolarity, having reduced TNF-?induction having a mutation in one or more lipid biosynthesis genes, e.g., msbB, rendered stress-resistant by a mutation in the zwf gene are provided. Methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering preferably attenuated stress-resistant gram-negative bacterial mutants. and for prophylaxis or treatment of a virally induced disease in a subject comprising administering one or more stress-resistant gram-negative bacterial mutants as vectors for the delivery of one or more therapeutic molecules are provided.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: February 11, 2014
    Assignee: Aviex Technologies, LLC
    Inventor: David Gordon Bermudes
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Publication number: 20140004150
    Abstract: The invention provides a vaccine injection, which includes a vaccine and a Traditional Chinese medicinal adjuvant in a mass ratio of 1:0.5-1:10, or a vaccine, a Traditional Chinese medicinal adjuvant and an aluminum adjuvant in a mass ratio of 1:0.5:2.5-1:10:20. The vaccine injection is in the form of powders, and the size of the powders is between 10 and 120 micrometers. The vaccine injection of the present invention is particularly suitable for the needle free injection technology. The invention also provides a preparation method for the vaccine injection.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 2, 2014
    Applicants: CHINA 302 MILITARY HOSPITAL OF PLA
    Inventors: Jiabo Wang, Xiaohe Xiao, Zhewei Wang, Cheng Jin, Qi Li
  • Publication number: 20130337013
    Abstract: The present invention encompasses recombinant bacteria suitable for live attenuated vaccines, and methods of use thereof. One aspect of the present invention encompasses a recombinant Salmonella bacterium. The bacterium comprises a first promoter operably linked to a nucleic acid encoding a toxin and a second promoter operably linked to a nucleic acid encoding an antitoxin, wherein the second promoter is inactive in vivo, but active in vitro.
    Type: Application
    Filed: November 22, 2011
    Publication date: December 19, 2013
    Applicant: The Arizona Board of Regents for and on behalf of Arizona State University
    Inventor: Melha Mellata
  • Patent number: 8604178
    Abstract: Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD 154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: December 10, 2013
    Assignees: The Board of Trustees of the University of Arkansas, The Texas A&M University of System
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton
  • Patent number: 8591862
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: November 26, 2013
    Assignee: Engeneic Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid
  • Patent number: 8586058
    Abstract: Method for producing multiple modifications in the chromosome of Gram-negative bacteria and Salmonella strains which are deficient in c-di-GMP synthesis obtained by said method. The method can be used to make multiple modifications in the genome of Gram-negative bacteria, simply and efficiently, using the plasmids of the invention, which comprise a marker gene under the control of a constitutive promoter, a replication origin specific for Gram-negative bacteria, a gene which encodes a heat-sensitive protein essential for initiating replication of the plasmid, making the replication origin heat-sensitive, and a counter-selection gene. The invention also relates to mutant Salmonella enterica strains obtained using the method of the invention in which some of the twelve genes which encode proteins with GGDEF domain have been selected*, and to the use thereof as expression vectors, immunotherapeutic agents and in metabolic studies.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: November 19, 2013
    Assignees: Universidad Publica de Navarra, Consejo Superior de Investigaciones Cientificas
    Inventors: Cristina Solano, Begoña García, Alejandro Toledo-Arana, Cristina Latasa, Violeta Zorraquino, Jaione Valle, Iñigo Lasa
  • Publication number: 20130266612
    Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 10, 2013
    Applicants: OSAKA UNIVERSITY, NITTO DENKO CORPORATION
    Inventors: Masahiro FUKASAKA, Arimichi OKAZAKI, Daisuke ASARI, Mitsuhiko HORI, Shizuo AKIRA, Osamu TAKEUCHI
  • Publication number: 20130251748
    Abstract: The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or E. coli in central nervous system and/or peripheral blood circulation, which comprises administering an effective amount of an OmpK36/homologues or its derivatives to the mammal.
    Type: Application
    Filed: July 10, 2012
    Publication date: September 26, 2013
    Applicant: NATIONAL DEFENSE MEDICAL CENTER
    Inventors: Leung-Kei Siu, Feng-Yee Chang, Yung-Chung Lin, Chang-Phone Fung, Yip-Mei Liu, Jiun-Han Chen, Yu-Kuo Tsai, Pele Choi-Sing Chong, Chih-Hsiang Leng, Shih-Jen Liu, Hsin-Wei Chen
  • Patent number: 8524243
    Abstract: The present invention relates to avirulent Salmonella Gallinarum variants by inactivating virulence gene clusters of Salmonella Gallinarum (SG), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of Salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: September 3, 2013
    Assignee: CJ Cheiljedang Corporation
    Inventors: Hyang Choi, Soo An Shin, Si Yong Yang, Young Wook Cho
  • Publication number: 20130202643
    Abstract: The present invention relates to avirulent Salmonella Gallinarum variants by inactivating virulence gene clusters of Salmonella Gallinarum (SG), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of Salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.
    Type: Application
    Filed: April 4, 2013
    Publication date: August 8, 2013
    Applicant: CJ CHEILJEDANG CORPORATION
    Inventor: CJ CHEILJEDANG CORPORATION
  • Patent number: 8486408
    Abstract: Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: July 16, 2013
    Assignee: Emory University
    Inventors: Mohammad S. Hossain, Andrew T. Gewitz, John D. Roback, Edmund K. Waller
  • Patent number: 8481052
    Abstract: The present invention relates to avirulent Salmonella gallinarum variants by inactivating virulence gene clusters of Salmonella gallinarum (SG), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of Salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: July 9, 2013
    Assignee: CJ Cheiljedang Corporation
    Inventors: Hyang Choi, Soo An Shin, Si Yong Yang, Young Wook Cho
  • Patent number: 8475810
    Abstract: The present invention is drawn to a live, attenuated S. Paratyphi A strain, a live, attenuated S. Paratyphi A strain comprising a stabilized plasmid expression system, and methods of using these strains.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: July 2, 2013
    Assignee: University of Maryland, Baltimore
    Inventors: Christofer Vindurampulle, Eileen M. Barry, Myron M. Levine
  • Patent number: 8465755
    Abstract: The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: June 18, 2013
    Assignee: The Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Melha Mellata, Bereket Zekarias, Zhaoxing Shi, Christine Branger, Kenneth Roland
  • Patent number: 8465749
    Abstract: Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: June 18, 2013
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Che-Hung Robert Lee, Carl E. Frasch
  • Patent number: 8449891
    Abstract: The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliC?190-278, FliC?220-320 or FliC?180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: May 28, 2013
    Assignee: Wuhan Institute of Virology, Chinese Academy of Sciences
    Inventors: Huimin Yan, Fang Liu, Jingyi Yang
  • Patent number: 8440207
    Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 14, 2013
    Assignee: Aviex Technologies, LLC
    Inventor: David Gordon Bermudes
  • Patent number: 8435506
    Abstract: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 7, 2013
    Assignee: North Carolina State University
    Inventors: Hosni M. Hassan, Ryan C. Fink, Matthew R. Evans
  • Patent number: 8425916
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: April 23, 2013
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Publication number: 20130052230
    Abstract: The present invention relates to novel Salmonella mutants, to a process for producing same and to vaccines containing same, wherein said Salmonella mutants are characterized in that they elicit a humoral response that can be distinguished from the humoral response elicited by the wild type strains. It is accordingly an object of the present invention to provide the use of said Salmonella mutants as serological marker strains in the vaccination of animals, in particular mammals and birds, more in particular cattle, poultry and pigs. The serological marker vaccine is of special value in animal farming and provides a (long-lasting) immunization against a wide range of Salmonella strains. The novel mutants are non-reverting and can be used for the efficient immunization of mammals and birds.
    Type: Application
    Filed: January 26, 2011
    Publication date: February 28, 2013
    Applicant: UNIVERSITEIT GENT
    Inventors: Filip Boyen, Frank Pasmans, Freddy Haesebrouck
  • Publication number: 20130028936
    Abstract: The present invention concerns a pharmaceutical composition comprising at least one agonist of at least one Toll Like receptor (TLR) chosen from TLR 4 and 9, for use in the prophylactic treatment of septic complications of post-traumatic systemic immunodepression in a patient who has suffered one or more severe traumatic injuries and is hospitalized in particular in an intensive care unit. Preferably, said TLR 4 agonist is monophosphoryl lipid A (MPLA) or deacylated 3-O-monophosphoryl lipid A (3D-MPLA) and said TLR 9 agonist is a CpG oligodeoxynucleotide (CpG ODN).
    Type: Application
    Filed: December 17, 2010
    Publication date: January 31, 2013
    Applicants: UNIVERSITE DE NANTES, CHU NANTES
    Inventor: Karim Asehnoune